Publication
Relapse and disease free survival in early stages of non-small-cell lung cancer
| Summary: | Cancer is one of the main causes of death in the world and the number of new cases is increasing every year. Lung cancer is the most frequently diagnosed type of cancer and first cause of death from cancer in the world, [2]. Based upon the microscopic appearance of tumor cells, lung cancers are classified into two main types: small cell lung cancer (15–20%) and non-small cell lung cancer (80–85%). Surgery remains the only potentially curative treatment for early-stage Non-Small-cell Lung Cancer (NSCLC) patients. However, 30% to 55% of patients with NSCLC develop recurrence and die of their disease despite curative resection, [3]. Cancer recurrence is defined by the reappearance of the cancer after the patient has been reported as cured. It may resurface in the same area where it was first found or turn up at another spot in the body. A multinomial logistic regression model was implemented to study the probability of recurrence for a real-life cohort of patients with stage I-II NSCLC treated at a tertiary hospital in Madrid, Spain. This method also helped to understand which factors might impact the recurrence of the cancer in the patients. This study was performed for three different timelines: 1 year, 3 years and 5 years after surgery. A simultaneous study of the Disease Free Survival Time was performed using a gener- alized linear model. This study was helpful in understanding the factors that contribute to a longer survival time without the disease after surgical treatment and allowed for the estimation of the disease free survival time as a function of the patients’ characteristics. This dissertation was carried out within the scope of the European CLARIFY project (https://www.clarify2020.eu/), in close collaboration with the oncology department of the University Hospital Puerta Hierro de Majadahonda. |
|---|---|
| Main Authors: | Lemos, Joana Filipa Sousa |
| Subject: | Recurrence Non-small-cell lung cancer (NSCLC) Surgery Multinomial logistic regression Disease free survival time Generalized linear models |
| Year: | 2022 |
| Country: | Portugal |
| Document type: | master thesis |
| Access type: | open access |
| Associated institution: | Universidade Nova de Lisboa |
| Language: | English |
| Origin: | Repositório Institucional da UNL |
| Summary: | Cancer is one of the main causes of death in the world and the number of new cases is increasing every year. Lung cancer is the most frequently diagnosed type of cancer and first cause of death from cancer in the world, [2]. Based upon the microscopic appearance of tumor cells, lung cancers are classified into two main types: small cell lung cancer (15–20%) and non-small cell lung cancer (80–85%). Surgery remains the only potentially curative treatment for early-stage Non-Small-cell Lung Cancer (NSCLC) patients. However, 30% to 55% of patients with NSCLC develop recurrence and die of their disease despite curative resection, [3]. Cancer recurrence is defined by the reappearance of the cancer after the patient has been reported as cured. It may resurface in the same area where it was first found or turn up at another spot in the body. A multinomial logistic regression model was implemented to study the probability of recurrence for a real-life cohort of patients with stage I-II NSCLC treated at a tertiary hospital in Madrid, Spain. This method also helped to understand which factors might impact the recurrence of the cancer in the patients. This study was performed for three different timelines: 1 year, 3 years and 5 years after surgery. A simultaneous study of the Disease Free Survival Time was performed using a gener- alized linear model. This study was helpful in understanding the factors that contribute to a longer survival time without the disease after surgical treatment and allowed for the estimation of the disease free survival time as a function of the patients’ characteristics. This dissertation was carried out within the scope of the European CLARIFY project (https://www.clarify2020.eu/), in close collaboration with the oncology department of the University Hospital Puerta Hierro de Majadahonda. |
|---|